References
- Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.Eur Heart J. 2021; 42:373–498.
- January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019; 74:104–32.
- Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, et al. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost. 2022; 122:20–47.
- Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018; 154:1121–201.
- Krittayaphong R, Winijkul A, Methavigul K, Wongtheptien W, Wongvipaporn C, Wisaratapong T, et al. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study. BMC Cardiovasc Disord. 2018; 18:174. doi: 10.1186/s12872-018-0911-4
- Methavigul K, Boonyapisit W. Optimal INR level in Thai atrial fibrillation patients who were receiving warfarin for stroke prevention in Thailand. J Med Assoc Thai. 2014; 97:1274–80.
- Methavigul K. Use of SAMe-TT2R2 score to predict the quality of anticoagulation control in patients with atrial fibrillation receiving warfarin in Thailand. J Med Assoc Thai. 2020; 103:548–52.
- Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008; 1:84–91.
- Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF Registry. PLoS One. 2016; 11:e0164076. doi: 10.1371/journal.pone.0164076
- Krittayaphong R, Chantrarat T, Rojjarekampai R, Jittham P, Sairat P, Lip GYH. Poor time in therapeutic range control is associated with adverse clinical outcomes in patients with non-valvular atrial fibrillation: a report from the nationwide COOL-AF registry. J Clin Med. 2020; 9:1698. doi: 10.3390/jcm9061698
- Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest. 2013; 144:1555–63.
- Lip GYH, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT2R2 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014; 146:719–26.
- Proietti M, Lane DA, Lip GY. Relation of the SAMe-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: observations from the SPORTIF trials. Int J Cardiol. 2016; 216:168–72.
- Chan PH, Hai JJ, Chan EW, Li WH, Tse HF, Wong IC, et al. Use of the SAMe-TT2R2score to predict good anticoagulation control with warfarin in Chinese patients with atrial fibrillation: relationship to ischemic stroke incidence. PLoS One. 2016; 11:e0150674. doi: 10.1371/journal.pone.0150674
- Bernaitis N, Ching CK, Chen L, Hon JS, Teo SC, Davey AK, et al. The sex, age, medical history, treatment, tobacco use, race risk (SA Me TT(2)R(2)) score predicts warfarin control in a Singaporean population. J Stroke Cerebrovasc Dis. 2017; 26:64–9.
- Methavigul K. Proportion of Thai patients with atrial fibrillation receiving warfarin with labile INR in each group of SAMeTT2R2 score. J Med Assoc Thai. 2018; 101:189–93.
- Krittayaphong R, Winijkul A, Pirapatdit A, Chiewvit P, Komoltri C, Boonyapisit W, et al. SAMe-TT2R2score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation. Singapore Med J. 2020; 61:641–6.
- Zhang H, Yang Y, Zhu J. The SAMe-TT(2)R(2) score: far from clinical application. Chest. 2014; 145:418–9.
- Methavigul K, Yindeengam A, Krittayaphong R. Efficacy and safety outcomes of patients with atrial fibrillation compared between warfarin and non-vitamin K antagonist oral anticoagulants based on SAMe-TT(2)R(2) score. BMC Cardiovasc Disord. 2023; 23:43. doi: 10.1186/s12872-023-03053-w
- Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69:236–9.
- Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27:157–72; discussion 207-112.